<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id><journal-id journal-id-type="publisher-id">CMH</journal-id><journal-title-group><journal-title>Clinical and Molecular Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2287-2728</issn><issn pub-type="epub">2287-285X</issn><publisher><publisher-name>The Korean Association for the Study of the Liver</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28081595</article-id><article-id pub-id-type="pmc">5266348</article-id><article-id pub-id-type="doi">10.3350/cmh.2016.0108</article-id><article-id pub-id-type="publisher-id">cmh-2016-0108</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Song</surname><given-names>Byung-Cheol</given-names></name><xref ref-type="corresp" rid="c1-cmh-2016-0108"/></contrib><aff id="af1-cmh-2016-0108">
Department of Internal Medicine, Jeju National University School of Medicine, Jeju, <country>Korea</country></aff></contrib-group><author-notes><corresp id="c1-cmh-2016-0108">Corresponding author : Byung-Cheol Song Department of Internal Medicine, Jeju National University School of Medicine, 15 Aran 13-gil, Jeju 63241, Korea Tel: + 82-64-754-8177, Fax: + 82-64-717-1131 E-mail: <email>drsong8177@naver.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>25</day><month>12</month><year>2016</year></pub-date><volume>22</volume><issue>4</issue><fpage>439</fpage><lpage>442</lpage><history><date date-type="received"><day>4</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 by The Korean Association for the Study of the Liver</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><kwd-group><kwd>Chronic hepatitis B</kwd><kwd>Adefovir</kwd><kwd>Tenofovir</kwd><kwd>Lamivudine resistance</kwd><kwd>Suboptimal response</kwd></kwd-group></article-meta></front><body><p>See Article on Page <related-article related-article-type="commentary-article" id="d35e108" vol="22" page="443" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="27880997" ext-link-type="pubmed">443</related-article></p><p>Hepatitis B virus (HBV), a major cause of liver disease, has infected approximately 2 billion people worldwide, and more than 350 million are chronically infected [<xref rid="b1-cmh-2016-0108" ref-type="bibr">1</xref>]. Persistent viral replication increases the risk of progression to liver cirrhosis, development of hepatocellular carcinoma (HCC) and liver-related death [<xref rid="b2-cmh-2016-0108" ref-type="bibr">2</xref>-<xref rid="b4-cmh-2016-0108" ref-type="bibr">4</xref>]. Therefore, the goals of antiviral therapy are to improve quality of life and survival by preventing progression of the disease to cirrhosis, HCC and death [<xref rid="b5-cmh-2016-0108" ref-type="bibr">5</xref>,<xref rid="b6-cmh-2016-0108" ref-type="bibr">6</xref>]. These goals can be achieved if HBV replication can be suppressed completely. Recent clinical studies showed that long-term suppression of HBV replication using anti-viral agents in patients with CHB can prevent progression to liver cirrhosis, hepatic failure and the development of HCC [<xref rid="b2-cmh-2016-0108" ref-type="bibr">2</xref>-<xref rid="b5-cmh-2016-0108" ref-type="bibr">5</xref>,<xref rid="b7-cmh-2016-0108" ref-type="bibr">7</xref>-<xref rid="b9-cmh-2016-0108" ref-type="bibr">9</xref>].</p><p>Lamivudine (LAM), adefovir dipivoxil (ADV), telbivudine (Ltd), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are available nucleos(t)ide analogues (NAs) for treating CHB patients worldwide. However, long-term treatment with NAs other than ETV and TDF increase the risk of drug resistance up to 80% because of low antiviral efficacy and low genetic barrier [<xref rid="b10-cmh-2016-0108" ref-type="bibr">10</xref>-<xref rid="b14-cmh-2016-0108" ref-type="bibr">14</xref>], Therefore, most guidelines recommend peg-interferon, ETV, or TDF in treatment-na&#x000ef;ve patients [<xref rid="b5-cmh-2016-0108" ref-type="bibr">5</xref>,<xref rid="b15-cmh-2016-0108" ref-type="bibr">15</xref>].</p><p>ADV add-on therapy has been widely used as a rescue therapy for patients with LAM-resistant CHB before TDF was not available [<xref rid="b6-cmh-2016-0108" ref-type="bibr">6</xref>,<xref rid="b16-cmh-2016-0108" ref-type="bibr">16</xref>]. However, suboptimal response has been commonly observed in patients receiving ADV-based therapy [<xref rid="b17-cmh-2016-0108" ref-type="bibr">17</xref>-<xref rid="b19-cmh-2016-0108" ref-type="bibr">19</xref>].</p><p>TDF, one of very potent antiviral agent with a high genetic barrier, showed excellent virologic response (VR), defined as serum HBV DNA level undetectably by sensitive PCR method, in NAs-na&#x000ef;ve [<xref rid="b20-cmh-2016-0108" ref-type="bibr">20</xref>,<xref rid="b21-cmh-2016-0108" ref-type="bibr">21</xref>] and NAs-resistant patients [<xref rid="b22-cmh-2016-0108" ref-type="bibr">22</xref>-<xref rid="b26-cmh-2016-0108" ref-type="bibr">26</xref>]. Clinical efficacies of TDF therapy in NA-na&#x000ef;ve and experienced patients are summarized in <xref rid="t1-cmh-2016-0108" ref-type="table">Table 1</xref>. In NA na&#x000ef;ve patients, a significantly higher proportion of patients receiving TDF than of those receiving ADV had reached VR at 48 weeks (<xref rid="t1-cmh-2016-0108" ref-type="table">Table 1</xref>). Almost all patients who received TDF therapy showed VR without any evidence of resistance at seven year [<xref rid="b14-cmh-2016-0108" ref-type="bibr">14</xref>]. In patients with LAM-resistant patients receiving TDF or TDF/emtricitabine (FTC), VR achieved in 89.4% and 86.3% at 96 weeks of therapy, respectively [<xref rid="b24-cmh-2016-0108" ref-type="bibr">24</xref>], without any evidence of TDF resistance during 5 years of follow-up [<xref rid="b27-cmh-2016-0108" ref-type="bibr">27</xref>]. TDF also showed high rate of VR in patients with ETV resistance [<xref rid="b26-cmh-2016-0108" ref-type="bibr">26</xref>]. In a randomized controlled trial conducted by Lim et al. [<xref rid="b26-cmh-2016-0108" ref-type="bibr">26</xref>] the proportion of patients with HBV DNA &#x0003c;15 IU/mL was high in patients who received TDF and TDF+ETV groups (71% vs. 73%; <italic>P</italic>=0.99). In patients with ADV-resistant patients with prior LAM resistance, the proportion of patients with HBV DNA &#x0003c;15 IU/mL was not significantly different between the TDF-TDF and TDF/ETV-TDF groups at weeks 48 (62% vs. 63.5%; <italic>P</italic>=0.88) and 96 (64% vs. 63.5%; <italic>P</italic>=0.96), suggesting that TDF monotherapy or combination therapy is effective even in patients with NAs-resistant patients.</p><p>There are several studies to evaluate the antiviral efficacy of TDF monotherapy or combination in patients with suboptimal response to ADV with or without prior resistance to LAM [<xref rid="b23-cmh-2016-0108" ref-type="bibr">23</xref>,<xref rid="b28-cmh-2016-0108" ref-type="bibr">28</xref>,<xref rid="b29-cmh-2016-0108" ref-type="bibr">29</xref>]. Berg, et al. conducted a randomized controlled trial to compare the anti-viral efficacy of TDF-based therapy for patients with CHB who had a suboptimal response to ADV (73% of the patients had received prior LAM therapy). A TDF monotherapy and TDF+FTC combination therapy showed similar VR at 48 week (81% vs. 81%) [<xref rid="b23-cmh-2016-0108" ref-type="bibr">23</xref>]. Cho et al. reported that the rate of VR was about 86.5 % through TDF monotherapy or TDF-based combination therapy in CHB patients with suboptimal responses to ADV plus LAM combination therapy [<xref rid="b28-cmh-2016-0108" ref-type="bibr">28</xref>]. Park et al. reported that the rate of VR was significantly higher in patients receiving TDV+ETV than in those receiving ADV+ETV for 12 months (84.8% vs. 26.7%, <italic>P</italic>&#x0003c;0.001) [<xref rid="b29-cmh-2016-0108" ref-type="bibr">29</xref>]. However, little randomized controlled trials are available to compare between to switch into TDF-based therapy or to continue ADV-based therapy in CHB patients with suboptimal response to ADV-based therapy.</p><p>In the current issue, Lee et al. [<xref rid="b30-cmh-2016-0108" ref-type="bibr">30</xref>] conducted a randomized controlled trial to compare the antiviral efficacy comparing between switching to TDF+NAs therapy and continuing current ADV+NA therapy in patients with suboptimal response to ADV-based therapy. They clearly showed that TDF+NAs therapy provide better VR compared to continue ADV+ NA who showed suboptimal response to ADV-based therapy (87.5% vs. 37.5% at 48 weeks, <italic>P</italic>=0.002).</p><p>However, there are several limitations of the study. First, even though the study was designed as a randomized controlled trial, the sample size was very small to conclude the results. Second, in this study, there was no TDF monotherapy group because TDF monotherapy and TDF+NAs combination therapy did not show any difference in VR in NA-experienced patients (<xref rid="t1-cmh-2016-0108" ref-type="table">Table 1</xref>). In addition, Yang et al. [<xref rid="b31-cmh-2016-0108" ref-type="bibr">31</xref>] compared the antiviral efficacy between switching to TDF monotherapy and continuing ADV+LAM combination therapy in patients with suboptimal response to ADV+LAM (prior LAM resistance patients) therapy. TDF monotherapy showed higher VR compared with continuing ADV+LAM combination therapy (96.43% vs. 29.0%; <italic>P</italic>&#x0003c;0.001). ADV monotherapy in patients with LAM resistance increase the risk of drug resistance [<xref rid="b17-cmh-2016-0108" ref-type="bibr">17</xref>-<xref rid="b19-cmh-2016-0108" ref-type="bibr">19</xref>]. Therefore, there is a concern about selective pressure on pre-existing resistant mutant viruses [<xref rid="b32-cmh-2016-0108" ref-type="bibr">32</xref>]. However, clonal analysis revealed that there is no significant selective pressure on pre-existing ADV or LAM resistant strains in during NA monotherpay patients with CHB and suboptimal response to ADV therapy who receiving TDF or TDF+FTC combination therapy [<xref rid="b33-cmh-2016-0108" ref-type="bibr">33</xref>].</p><p>In conclusion, considering the result from current study [<xref rid="b30-cmh-2016-0108" ref-type="bibr">30</xref>] and previous studies [<xref rid="b23-cmh-2016-0108" ref-type="bibr">23</xref>-<xref rid="b26-cmh-2016-0108" ref-type="bibr">26</xref>,<xref rid="b31-cmh-2016-0108" ref-type="bibr">31</xref>], TDF with or without NAs might be very effective to treat the patient with suboptimal response to ADV-based therapy.</p></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Conflicts of Interest:</bold> The author has no conflicts to disclose.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>ADV</term><def><p>adefovir dipivoxil</p></def></def-item><def-item><term>CHB</term><def><p>chronic hepatitis B</p></def></def-item><def-item><term>ETV</term><def><p>entecavir</p></def></def-item><def-item><term>HBV</term><def><p>hepatitis B virus</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>LAM</term><def><p>lamivudine</p></def></def-item><def-item><term>TDF</term><def><p>tenofovir disoproxil fumarate</p></def></def-item><def-item><term>VR</term><def><p>virologic response</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="b1-cmh-2016-0108"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavanchy</surname><given-names>D</given-names></name></person-group><article-title>Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures</article-title><source>J Viral Hepat</source><year>2004</year><volume>11</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">14996343</pub-id></element-citation></ref><ref id="b2-cmh-2016-0108"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liaw</surname><given-names>YF</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name><name><surname>Chow</surname><given-names>WC</given-names></name><name><surname>Farrell</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>CZ</given-names></name><name><surname>Yuen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Lamivudine for patients with chronic hepatitis B and advanced liver disease</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1521</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">15470215</pub-id></element-citation></ref><ref id="b3-cmh-2016-0108"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosaka</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>F</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Seko</surname><given-names>Y</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Sezaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection</article-title><source>Hepatology</source><year>2013</year><volume>58</volume><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">23213040</pub-id></element-citation></ref><ref id="b4-cmh-2016-0108"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>GL</given-names></name><name><surname>Chan</surname><given-names>HL</given-names></name><name><surname>Mak</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Ip</surname><given-names>ZM</given-names></name><name><surname>Lam</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis</article-title><source>Hepatology</source><year>2013</year><volume>58</volume><fpage>1537</fpage><lpage>1547</lpage><pub-id pub-id-type="pmid">23389810</pub-id></element-citation></ref><ref id="b5-cmh-2016-0108"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL clinical practice guidelines: Management of chronic hepatitis B virus infection</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><fpage>167</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">22436845</pub-id></element-citation></ref><ref id="b6-cmh-2016-0108"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Korean Association for the Study of the Liver</collab></person-group><article-title>KASL Clinical Practice Guidelines: Management of chronic hepatitis B</article-title><source>Clin Mol Hepatol</source><year>2012</year><volume>18</volume><fpage>109</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">22893865</pub-id></element-citation></ref><ref id="b7-cmh-2016-0108"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiff</surname><given-names>ER</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Chao</surname><given-names>YC</given-names></name><name><surname>Kew Yoon</surname><given-names>S</given-names></name><name><surname>Bessone</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B</article-title><source>Clin Gastroenterol Hepatol</source><year>2011</year><volume>9</volume><fpage>274</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">21145419</pub-id></element-citation></ref><ref id="b8-cmh-2016-0108"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Liaw</surname><given-names>YF</given-names></name><name><surname>Wu</surname><given-names>SS</given-names></name><name><surname>Schiff</surname><given-names>E</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">20683932</pub-id></element-citation></ref><ref id="b9-cmh-2016-0108"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Afdhal</surname><given-names>N</given-names></name><name><surname>Sievert</surname><given-names>W</given-names></name><name><surname>Jacobson</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">23234725</pub-id></element-citation></ref><ref id="b10-cmh-2016-0108"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dienstag</surname><given-names>JL</given-names></name><name><surname>Cianciara</surname><given-names>J</given-names></name><name><surname>Karayalcin</surname><given-names>S</given-names></name><name><surname>Kowdley</surname><given-names>KV</given-names></name><name><surname>Willems</surname><given-names>B</given-names></name><name><surname>Plisek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Durability of serologic response after lamivudine treatment of chronic hepatitis B</article-title><source>Hepatology</source><year>2003</year><volume>37</volume><fpage>748</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">12668966</pub-id></element-citation></ref><ref id="b11-cmh-2016-0108"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Leung</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>GB</given-names></name><name><surname>Cui</surname><given-names>ZY</given-names></name><name><surname>Schiff</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Long-term safety of lamivudine treatment in patients with chronic hepatitis B</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><fpage>1714</fpage><lpage>1722</lpage><pub-id pub-id-type="pmid">14724824</pub-id></element-citation></ref><ref id="b12-cmh-2016-0108"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Dienstag</surname><given-names>J</given-names></name><name><surname>Schiff</surname><given-names>E</given-names></name><name><surname>Leung</surname><given-names>NW</given-names></name><name><surname>Atkins</surname><given-names>M</given-names></name><name><surname>Hunt</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">12627352</pub-id></element-citation></ref><ref id="b13-cmh-2016-0108"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Kew Yoon</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Coelho</surname><given-names>HS</given-names></name><name><surname>Carrilho</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">20049753</pub-id></element-citation></ref><ref id="b14-cmh-2016-0108"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Tsai</surname><given-names>N</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Flisiak</surname><given-names>R</given-names></name><name><surname>Gurel</surname><given-names>S</given-names></name><name><surname>Krastev</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Sevenyear efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection</article-title><source>Dig Dis Sci</source><year>2015</year><volume>60</volume><fpage>1457</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">25532501</pub-id></element-citation></ref><ref id="b15-cmh-2016-0108"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Korean Association for the Study of the Liver</collab></person-group><article-title>KASL clinical practice guidelines: management of chronic hepatitis B</article-title><source>Clin Mol Hepatol</source><year>2016</year><volume>22</volume><fpage>18</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">27044762</pub-id></element-citation></ref><ref id="b16-cmh-2016-0108"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>McMahon</surname><given-names>BJ</given-names></name></person-group><article-title>Chronic hepatitis B</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>507</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">17256718</pub-id></element-citation></ref><ref id="b17-cmh-2016-0108"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>SP</given-names></name><name><surname>Kim</surname><given-names>SO</given-names></name><etal/></person-group><article-title>Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B</article-title><source>Antivir Ther</source><year>2010</year><volume>15</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">20386079</pub-id></element-citation></ref><ref id="b18-cmh-2016-0108"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B</article-title><source>J Med Virol</source><year>2010</year><volume>82</volume><fpage>1835</fpage><lpage>1842</lpage><pub-id pub-id-type="pmid">20872709</pub-id></element-citation></ref><ref id="b19-cmh-2016-0108"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>BC</given-names></name><name><surname>Cui</surname><given-names>XJ</given-names></name><name><surname>Shin</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>NH</given-names></name><name><surname>Cho</surname><given-names>YK</given-names></name><name><surname>Song</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in lamivudine-resistant chronic hpatitis B ptients</article-title><source>Intervirology</source><year>2010</year><volume>53</volume><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">20332649</pub-id></element-citation></ref><ref id="b20-cmh-2016-0108"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Heathcote</surname><given-names>EJ</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name><name><surname>Krastev</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2442</fpage><lpage>2455</lpage><pub-id pub-id-type="pmid">19052126</pub-id></element-citation></ref><ref id="b21-cmh-2016-0108"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>JL</given-names></name><name><surname>Gao</surname><given-names>ZL</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>JM</given-names></name><name><surname>Sheng</surname><given-names>JF</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial</article-title><source>J Viral Hepat</source><year>2015</year><volume>22</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">25243325</pub-id></element-citation></ref><ref id="b22-cmh-2016-0108"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van B&#x000f6;mmel</surname><given-names>F</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Deterding</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Buggisch</surname><given-names>P</given-names></name><etal/></person-group><article-title>Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">19998272</pub-id></element-citation></ref><ref id="b23-cmh-2016-0108"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Zoulim</surname><given-names>F</given-names></name><name><surname>Moller</surname><given-names>B</given-names></name><name><surname>Trinh</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>1207</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">20600025</pub-id></element-citation></ref><ref id="b24-cmh-2016-0108"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>S</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Fabri</surname><given-names>M</given-names></name><name><surname>Horban</surname><given-names>A</given-names></name><name><surname>Pelemis</surname><given-names>M</given-names></name><name><surname>Hann</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>980</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">24368224</pub-id></element-citation></ref><ref id="b25-cmh-2016-0108"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YS</given-names></name><name><surname>Yoo</surname><given-names>BC</given-names></name><name><surname>Byun</surname><given-names>KS</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>An</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>1045</fpage><lpage>1051</lpage></element-citation></ref><ref id="b26-cmh-2016-0108"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YS</given-names></name><name><surname>Byun</surname><given-names>KS</given-names></name><name><surname>Yoo</surname><given-names>BC</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>An</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>852</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">25596179</pub-id></element-citation></ref><ref id="b27-cmh-2016-0108"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>S</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Fabri</surname><given-names>M</given-names></name><name><surname>Horban</surname><given-names>A</given-names></name><name><surname>Pelemis</surname><given-names>M</given-names></name><name><surname>Hann</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study</article-title><source>J Hepatol</source><year>2016</year><month>8</month><day>18</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="b28-cmh-2016-0108"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Yoo</surname><given-names>BM</given-names></name><name><surname>Cho</surname><given-names>SW</given-names></name><name><surname>Cheong</surname><given-names>JY</given-names></name></person-group><article-title>Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance</article-title><source>J Med Virol</source><year>2015</year><volume>87</volume><fpage>1532</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">25940352</pub-id></element-citation></ref><ref id="b29-cmh-2016-0108"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name></person-group><article-title>Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy</article-title><source>Clin Mol Hepatol</source><year>2015</year><volume>21</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">26523269</pub-id></element-citation></ref><ref id="b30-cmh-2016-0108"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>BK</given-names></name><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>JI</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who have suboptimal response to adefovir-based combination rescue therapy due to nucleoside analogues resistance (SATIS study)</article-title><source>Clin Mol Hepatol</source><year>2016</year><volume>22</volume><fpage>433</fpage><lpage>449</lpage></element-citation></ref><ref id="b31-cmh-2016-0108"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>DH</given-names></name><name><surname>Xie</surname><given-names>YJ</given-names></name><name><surname>Zhao</surname><given-names>NF</given-names></name><name><surname>Pan</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>MW</given-names></name><name><surname>Huang</surname><given-names>HJ</given-names></name></person-group><article-title>Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>2746</fpage><lpage>2753</lpage><pub-id pub-id-type="pmid">25759545</pub-id></element-citation></ref><ref id="b32-cmh-2016-0108"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>YK</given-names></name><name><surname>Cui</surname><given-names>XJ</given-names></name><name><surname>Jeong</surname><given-names>SU</given-names></name><name><surname>Song</surname><given-names>BC</given-names></name></person-group><article-title>Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B</article-title><source>Antiviral Res</source><year>2014</year><volume>112</volume><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">25303802</pub-id></element-citation></ref><ref id="b33-cmh-2016-0108"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavocat</surname><given-names>F</given-names></name><name><surname>D&#x000e9;ny</surname><given-names>P</given-names></name><name><surname>Pichoud</surname><given-names>C</given-names></name><name><surname>Al Hawajri</surname><given-names>N</given-names></name><name><surname>Kitrinos</surname><given-names>K</given-names></name><name><surname>Borroto-Esoda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy</article-title><source>J Hepatol</source><year>2013</year><volume>59</volume><fpage>684</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">23742912</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-cmh-2016-0108" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Summary of randomized controlled trials to evaluate the anti-viral efficacy of tenofovir-based therapy in patients with NAs-na&#x000ef;ve or experienced patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" rowspan="1" colspan="1">Study populations</th><th align="center" valign="middle" rowspan="1" colspan="1">Intervention</th><th align="center" valign="middle" rowspan="1" colspan="1">Primary efficacy end point</th><th align="center" valign="middle" rowspan="1" colspan="1">Virologic response</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">Marcellin et al. (2008) [<xref rid="b20-cmh-2016-0108" ref-type="bibr">20</xref>]</td><td align="left" valign="top" rowspan="3" colspan="1">NAs-na&#x000ef;ve</td><td align="left" valign="top" rowspan="1" colspan="1">TDF vs. ADV</td><td align="left" valign="top" rowspan="3" colspan="1">HBV DNA level &#x0003c;69 IU/mL at 48 week</td><td align="left" valign="top" rowspan="1" colspan="1">76% vs. 13% in HBeAg (+) patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBeAg (+) (n=266)</td><td align="left" valign="top" rowspan="2" colspan="1">96.8% vs. 71.2% in HBeAg (-) patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBeAg (-) (n=375)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fung et al. (2014) [<xref rid="b24-cmh-2016-0108" ref-type="bibr">24</xref>]</td><td align="left" valign="top" rowspan="1" colspan="1">LAM -resistant</td><td align="left" valign="top" rowspan="1" colspan="1">TDF (n=141) vs. TDF/FTC (n=139)</td><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA level &#x0003c;69 IU/mL at 96 week</td><td align="left" valign="top" rowspan="1" colspan="1">89.4% vs. 86.3 % (<italic>P</italic>=0.43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lim et al. (2016) [<xref rid="b25-cmh-2016-0108" ref-type="bibr">25</xref>]</td><td align="left" valign="top" rowspan="1" colspan="1">ADV-resistant (100% LAM-resistant)</td><td align="left" valign="top" rowspan="1" colspan="1">TDF (n=50) vs. TDF/ETV (n=52)</td><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA level &#x0003c;15 IU/mL at 48 week</td><td align="left" valign="top" rowspan="1" colspan="1">62% vs. 63.5% (<italic>P</italic>=0.88)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lim et al. (2016) [<xref rid="b26-cmh-2016-0108" ref-type="bibr">26</xref>]</td><td align="left" valign="top" rowspan="1" colspan="1">ETV-resistant</td><td align="left" valign="top" rowspan="1" colspan="1">TDF (n=45) vs. TDF/ETV (n=5)</td><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA level &#x0003c;15 IU/mL at 48 week</td><td align="left" valign="top" rowspan="1" colspan="1">71% vs. 73% (<italic>P</italic>=0.99)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Berg et al. (2010) [<xref rid="b23-cmh-2016-0108" ref-type="bibr">23</xref>]</td><td align="left" valign="top" rowspan="1" colspan="1">Suboptimal response to ADV (73% of the patients had received prior LAM therapy)</td><td align="left" valign="top" rowspan="1" colspan="1">TDF (n=53) vs. TDF/FTC (n=52)</td><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA level &#x0003c;69 IU/mL at 48 week</td><td align="left" valign="top" rowspan="1" colspan="1">81% vs. 81% (<italic>P</italic>=ns)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yang et al. (2015) [<xref rid="b31-cmh-2016-0108" ref-type="bibr">31</xref>]</td><td align="left" valign="top" rowspan="1" colspan="1">Suboptimal response to ADV/LAM (prior LAM resistance patients)</td><td align="left" valign="top" rowspan="1" colspan="1">TDF (n=28) vs. continue ADV/LAM (n=31)</td><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA level &#x0003c;200 IU/mL at 48 week</td><td align="left" valign="top" rowspan="1" colspan="1">96.43% vs. 29.0% (<italic>P</italic>&#x0003c;0.001)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lee et al. (2016) [<xref rid="b30-cmh-2016-0108" ref-type="bibr">30</xref>]</td><td align="left" valign="top" rowspan="1" colspan="1">Suboptimal response to ADV-based combination therapy due to NA resistance (LAM-resistant 9, Ldt-resistant 14, ETV-resistant 9)</td><td align="left" valign="top" rowspan="1" colspan="1">TDF +NA (n=16) vs. continue ADV+NA (n=16)</td><td align="left" valign="top" rowspan="1" colspan="1">HBV DNA level &#x0003c; 60 IU/mL at 48 week</td><td align="left" valign="top" rowspan="1" colspan="1">81.3% vs. 56.3% (<italic>P</italic>&#x0003c;0.001)</td></tr></tbody></table><table-wrap-foot><fn><p>ADV, adefovir dipivoxil; ETV, entecavir; TDF, tenofovir disoproxil fumarate; TDF/FTC, TDF/emtricitabine; LAM, lamivudine; NAs, nucleos(t)ide analogues.</p></fn></table-wrap-foot></table-wrap></floats-group></article>